---
figid: PMC3521191__1741-7015-10-112-1
figlink: /pmc/articles/PMC3521191/figure/F1/
number: F1
caption: 'Biological pathways targeted for therapy in renal cell carcinoma based on
  a knowledge of the underlying genetic changes and downstream biological consequences.
  Loss of function of the VHL tumour suppressor gene leads to stabilisation of hypoxia-inducible
  factor alpha (HIFα). Activated HIF translocates into the nucleus and leads to the
  transcription of a large number of hypoxia-inducible genes including vascular endothelial
  growth factor (VEGF) and platelet derived growth factor (PDGF). Mammalian target
  of rapamycin (mTOR) is a kinase within the PI3K/Akt pathway that can promote cell
  growth and survival pathways as well as causing accumulation of HIF. Bevacizumab
  is a monoclonal antibody to VEGF whilst sunitinib, sorafenib, axitinib and pazopanib
  are VEGF receptor tyrosine kinase inhibitors. These agents are thought to primarily
  function as antiangiogenic agents, inhibiting ligand binding or downstream receptor
  signalling of VEGF and PDGF on endothelial cells. Temsirolimus and everolimus inhibit
  the kinase activity of the mTOR complex 1 (mTORC1). Reproduced with permission from
  Elsevier©. From []. HIF: hypoxia-inducible factor; mTOR: mammalian target of rapamycin;
  mTORC1: mTOR complex 1; PDGF: platelet derived growth factor; PTEN: phosphatase
  and tensin homolog; VEGF: vascular endothelial growth factor; VEGFR: vascular endothelial
  growth factor receptor.'
pmcid: PMC3521191
papertitle: 'Renal cancer biomarkers: the promise of personalized care.'
reftext: Naveen S Vasudev, et al. BMC Med. 2012;10:112-112.
pmc_ranked_result_index: '125289'
pathway_score: 0.9019472
filename: 1741-7015-10-112-1.jpg
figtitle: Biological pathways targeted for therapy in renal cell carcinoma based on
  a knowledge of the underlying genetic changes and downstream biological consequences
year: '2012'
organisms:
- Homo sapiens
ndex: 9ee2d64a-df13-11ea-99da-0ac135e8bacf
annotations: []
seo: CreativeWork
schema-jsonld:
  '@context': https://schema.org/
  '@id': https://pfocr.wikipathways.org/figures/PMC3521191__1741-7015-10-112-1.html
  '@type': Dataset
  description: 'Biological pathways targeted for therapy in renal cell carcinoma based
    on a knowledge of the underlying genetic changes and downstream biological consequences.
    Loss of function of the VHL tumour suppressor gene leads to stabilisation of hypoxia-inducible
    factor alpha (HIFα). Activated HIF translocates into the nucleus and leads to
    the transcription of a large number of hypoxia-inducible genes including vascular
    endothelial growth factor (VEGF) and platelet derived growth factor (PDGF). Mammalian
    target of rapamycin (mTOR) is a kinase within the PI3K/Akt pathway that can promote
    cell growth and survival pathways as well as causing accumulation of HIF. Bevacizumab
    is a monoclonal antibody to VEGF whilst sunitinib, sorafenib, axitinib and pazopanib
    are VEGF receptor tyrosine kinase inhibitors. These agents are thought to primarily
    function as antiangiogenic agents, inhibiting ligand binding or downstream receptor
    signalling of VEGF and PDGF on endothelial cells. Temsirolimus and everolimus
    inhibit the kinase activity of the mTOR complex 1 (mTORC1). Reproduced with permission
    from Elsevier©. From []. HIF: hypoxia-inducible factor; mTOR: mammalian target
    of rapamycin; mTORC1: mTOR complex 1; PDGF: platelet derived growth factor; PTEN:
    phosphatase and tensin homolog; VEGF: vascular endothelial growth factor; VEGFR:
    vascular endothelial growth factor receptor.'
  license: CC0
  name: CreativeWork
  creator:
    '@type': Organization
    name: WikiPathways
  keywords:
  - MLST8
  - MYC
  - CCND1
  - PDGFA
  - VEGFA
  - VEGFD
  - AKT3
  - RPTOR
  - PDGFB
  - PDGFC
  - ARNTL
  - AKT1
  - PGF
  - VEGFB
  - VEGFC
  - AKT2
  - EPAS1
  - HIF3A
  - MTOR
  - HIF1A
  - PDGFD
  - EIF4EBP1
  - FLT4
  - PTEN
  - PDGFRA
  - ARNT2
  - FLT1
  - PDGFRB
  - ARNT
  - VHL
  - KDR
  - Temsirolimus
  - Pazopanib
  - Cancer
genes:
- word: GBL
  symbol: GbetaL
  source: hgnc_alias_symbol
  hgnc_symbol: MLST8
  entrez: '64223'
- word: c-Myc
  symbol: c-Myc
  source: hgnc_alias_symbol
  hgnc_symbol: MYC
  entrez: '4609'
- word: CyclinD1
  symbol: Cyclin-D1
  source: bioentities_symbol
  hgnc_symbol: CCND1
  entrez: '595'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFA
  entrez: '5154'
- word: VEGF.
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFA
  entrez: '7422'
- word: VEGF.
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFD
  entrez: '2277'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT3
  entrez: '10000'
- word: MTORC1
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: RPTOR
  entrez: '57521'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFB
  entrez: '5155'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFC
  entrez: '56034'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: ARNTL
  entrez: '406'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT1
  entrez: '207'
- word: MLST8
  symbol: MLST8
  source: hgnc_symbol
  hgnc_symbol: MLST8
  entrez: '64223'
- word: Raptor
  symbol: raptor
  source: hgnc_alias_symbol
  hgnc_symbol: RPTOR
  entrez: '57521'
- word: VEGF.
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: PGF
  entrez: '5228'
- word: VEGF.
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFB
  entrez: '7423'
- word: VEGF.
  symbol: VEGF
  source: bioentities_symbol
  hgnc_symbol: VEGFC
  entrez: '7424'
- word: Akt
  symbol: AKT
  source: bioentities_symbol
  hgnc_symbol: AKT2
  entrez: '208'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: EPAS1
  entrez: '2034'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: HIF3A
  entrez: '64344'
- word: MTORC1
  symbol: mTORC1
  source: bioentities_symbol
  hgnc_symbol: MTOR
  entrez: '2475'
- word: HIFa
  symbol: HIF_alpha
  source: bioentities_symbol
  hgnc_symbol: HIF1A
  entrez: '3091'
- word: HIFa
  symbol: HIF_alpha
  source: bioentities_symbol
  hgnc_symbol: EPAS1
  entrez: '2034'
- word: PDGF
  symbol: PDGF
  source: bioentities_symbol
  hgnc_symbol: PDGFD
  entrez: '80310'
- word: 4E-BP1
  symbol: 4E-BP1
  source: hgnc_alias_symbol
  hgnc_symbol: EIF4EBP1
  entrez: '1978'
- word: HIFa
  symbol: HIF_alpha
  source: bioentities_symbol
  hgnc_symbol: HIF3A
  entrez: '64344'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT4
  entrez: '2324'
- word: PTEN
  symbol: PTEN
  source: hgnc_symbol
  hgnc_symbol: PTEN
  entrez: '5728'
- word: PDGFR
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRA
  entrez: '5156'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: ARNT2
  entrez: '9915'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: FLT1
  entrez: '2321'
- word: PDGFR
  symbol: PDGFR
  source: bioentities_symbol
  hgnc_symbol: PDGFRB
  entrez: '5159'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: HIF1A
  entrez: '3091'
- word: HIF
  symbol: HIF
  source: bioentities_symbol
  hgnc_symbol: ARNT
  entrez: '405'
- word: VHL
  symbol: VHL
  source: hgnc_symbol
  hgnc_symbol: VHL
  entrez: '7428'
- word: VEGFR
  symbol: VEGFR
  source: bioentities_symbol
  hgnc_symbol: KDR
  entrez: '3791'
chemicals:
- word: Temsirolimus
  source: MESH
  identifier: C401859
- word: Pazopanib
  source: MESH
  identifier: C516667
diseases:
- word: Cancer
  source: ''
  identifier: ''
figid_alias: PMC3521191__F1
redirect_from: /figures/PMC3521191__F1
figtype: Figure
---
